Gossamer Bio, Inc.

NASDAQ:GOSS

Biotechnology

Healthcare
$11.04 +3.24%

+$0.01 today

Market cap
$67.52M
Beta
2.04
P/E (TTM)
-0.2
EPS (TTM)
-$0.77
52W Low $0.11High $3.87

Volume 0.22M

Average 19.76M

GOSS EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Gossamer Bio, Inc.NASDAQ: GOSS

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$43.68M, compared with -$33.55M a year earlier. Trailing-twelve-month EBITDA was -$168.81M.

Context

  • EBITDA amounted to 326.9% of revenue in FY2025, up 292.1 pp from a year earlier.
  • EBITDA grew in size in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 4 analysts of -$80.49M (+49.2%) for the fiscal year ending Dec 2026, a step up from the -296.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$43.68M+1.5% QoQ
Last fiscal yearDec 2025
-$158.47M-296.5% YoY
LTMMar 2026
-$168.81M-372.8% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-30.2%-74.2%-44.0 pp
1 year-296.5%+49.2%+345.7 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(158.47M) USD
Year-over-year change
-296.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How GOSS compares with its peers on the latest reported figures

  • GOSS's LTM Mar 2026 EBITDA of -$168.81M is the 7th highest of the 9 companies compared; the peer median is -$95.93M.
  • Its year-over-year change of -372.8% is the lowest of 8, against a peer median of +3.9%.
  • EBITDA amounts to 304.0% of revenue for GOSS, versus a peer median of 115.0%.
GOSS Competitors Peer median
EBITDA for GOSS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$131.28M +170.9%—43.8%
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026-$17.44M +88.7%—25.0%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026-$42.27M -2.3%——
PRTAProthena Corporation plcLTM Mar 2026-$74.72M +35.0%—129.0%
KALVKalVista Pharmaceuticals, Inc.LTM Dec 2025-$117.15M ——101.1%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026-$163.43M +3.9%—185.2%
GOSSGossamer Bio, Inc.LTM Mar 2026-$168.81M -372.8%—304.0%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026-$184.67M -43.8%——
RGNXREGENXBIO Inc.LTM Mar 2026-$229.35M -87.3%—261.2%
Peer median (excluding GOSS) -$95.93M+3.9%—115.0%

Competitors are the stored peer set for GOSS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000114.7M48.47M
Cost of Revenue00001M
Gross Profit000114.7M47.47M
Gross Margin———100.0%97.9%
Research & Development170.27M170.92M135.3M138.49M174.09M
Selling, General & Admin45.78M47.61M38.46M36.13M37.63M
Operating Expenses216.12M218.59M183.76M174.62M210.72M
Depreciation & Amortization5.17M4.43M4.39M4.15M1M
EBITDA(209.4M)(211.07M)(161.92M)(39.97M)(158.47M)
EBITDA Margin———-34.8%-326.9%
Operating Income(216.12M)(218.59M)(183.76M)(59.92M)(163.25M)
Operating Margin———-52.2%-336.8%
Interest Income761K1.58M2M1.78M1.97M
Interest Expense19.44M13.88M13.51M11.52M10.99M
Other Income / Expenses(17.88M)(10.79M)3.94M4.28M(7.21M)
Income Before Tax(234M)(229.38M)(179.82M)(55.64M)(170.46M)
Pre-Tax Margin———-48.5%-351.7%
Income Tax Expense000893K(88K)
Net Income(234M)(229.38M)(179.82M)(56.53M)(170.37M)
Net Margin———-49.3%-351.5%
EPS (Basic)(3.33)(2.84)(0.80)(0.25)(0.75)
EPS (Diluted)(3.33)(2.84)(1.18)(0.25)(0.75)
Weighted Avg Shares74.84M84.57M225.57M226.23M228.52M
Weighted Avg Shares (Diluted)74.84M84.57M225.57M226.23M228.52M

Gossamer Bio, Inc.

NASDAQ:GOSS

Intrinsic Alpha fair value

Locked

Current Price

$11.04

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.